Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by M&G Investment Management Ltd.

M&G Investment Management Ltd. lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 15.5% during the first quarter, Holdings Channel reports. The fund owned 101,302 shares of the biopharmaceutical company’s stock after selling 18,545 shares during the quarter. M&G Investment Management Ltd.’s holdings in Gilead Sciences were worth $6,585,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. ING Groep NV boosted its position in Gilead Sciences by 4.3% during the first quarter. ING Groep NV now owns 88,788 shares of the biopharmaceutical company’s stock worth $5,738,000 after acquiring an additional 3,643 shares during the last quarter. Elo Mutual Pension Insurance Co boosted its position in Gilead Sciences by 1.5% during the first quarter. Elo Mutual Pension Insurance Co now owns 90,434 shares of the biopharmaceutical company’s stock worth $5,845,000 after acquiring an additional 1,298 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in shares of Gilead Sciences by 38.8% in the 1st quarter. Mercer Global Advisors Inc. ADV now owns 57,076 shares of the biopharmaceutical company’s stock valued at $3,689,000 after purchasing an additional 15,954 shares during the last quarter. Stevens Capital Management LP acquired a new position in shares of Gilead Sciences in the 1st quarter valued at $779,000. Finally, Acadian Asset Management LLC boosted its holdings in shares of Gilead Sciences by 6.8% in the 1st quarter. Acadian Asset Management LLC now owns 2,469,803 shares of the biopharmaceutical company’s stock valued at $159,623,000 after purchasing an additional 158,183 shares during the last quarter. Hedge funds and other institutional investors own 77.18% of the company’s stock.

In other Gilead Sciences news, Director Richard James Whitley sold 20,282 shares of the firm’s stock in a transaction on Monday, May 3rd. The shares were sold at an average price of $64.57, for a total transaction of $1,309,608.74. Following the completion of the transaction, the director now directly owns 51,404 shares of the company’s stock, valued at approximately $3,319,156.28. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.12% of the stock is owned by company insiders.

Shares of GILD stock opened at $69.29 on Friday. The firm has a market cap of $86.90 billion, a price-to-earnings ratio of 301.27, a P/E/G ratio of 0.62 and a beta of 0.38. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.18 and a current ratio of 1.37. Gilead Sciences, Inc. has a 1-year low of $56.56 and a 1-year high of $78.94. The business’s fifty day moving average is $66.52.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 29th. The biopharmaceutical company reported $2.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.06 by $0.02. The company had revenue of $6.42 billion during the quarter, compared to analyst estimates of $6.78 billion. Gilead Sciences had a net margin of 1.18% and a return on equity of 51.91%. Equities research analysts predict that Gilead Sciences, Inc. will post 7.07 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 29th. Shareholders of record on Tuesday, June 15th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 4.10%. The ex-dividend date is Monday, June 14th. Gilead Sciences’s dividend payout ratio is currently 40.06%.

GILD has been the topic of a number of research analyst reports. Redburn Partners upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating in a report on Tuesday, March 30th. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating and set a $69.00 target price on the stock in a research note on Wednesday, May 5th. TheStreet raised shares of Gilead Sciences from a “c” rating to a “b-” rating in a research note on Tuesday, March 30th. Morgan Stanley raised their target price on shares of Gilead Sciences from $81.00 to $83.00 and gave the company an “overweight” rating in a research note on Monday, May 3rd. Finally, Sanford C. Bernstein raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $80.00 target price on the stock in a research note on Thursday, April 1st. Ten research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $99.22.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Featured Article: Diversification For Individual Investors

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.